Three things on the current FDA labels are worth knowing before you start. First, the labels for Zepbound and Foundayo say that these medicines can affect how oral hormonal contraceptives are absorbed, and they tell prescribers to advise a non-oral method or an added barrier method for a set period after starting and after each dose increase. Second, the Wegovy label says to stop the medicine at least 2 months before a planned pregnancy. Third, all three labels say that when a pregnancy is recognised, the medicine should be discontinued. What to do about any of this in your own situation is a conversation with your prescriber.
Why these medicines raise the question at all
GLP-1 receptor agonists and tirzepatide slow gastric emptying, which is part of how they work and part of why they cause nausea in some people. The Wegovy label states that the medicine “causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.” An oral contraceptive is an oral medication, so the question follows naturally: does a slower stomach change how well the pill works?
The answer on the labels depends on the product, and it is not the same across the three medicines covered here. That is why this article goes drug by drug and quotes the wording rather than summarising it into a single rule.
What each label says about oral contraceptives
| Medicine | What the label says about oral hormonal contraceptives |
|---|---|
| Zepbound (tirzepatide) | The prescribing information says use may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, and advises patients using them to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation. |
| Foundayo (orforglipron) | The prescribing information advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose escalation. It also states that the effect on absorption of oral contraceptives has not been evaluated in a clinical trial. |
| Wegovy (semaglutide) | The prescribing information notes the general effect on absorption of oral medications. The sections we reviewed did not contain a contraceptive-specific instruction comparable to the two above. Ask your prescriber how they apply the oral-medication warning to you. |
Two details are easy to miss. The first is that the instruction is tied to dose changes, not only to the first dose. Zepbound and Foundayo are both started low and increased in steps, so the periods the labels describe can recur several times in the first months. The second is that the labels address oral hormonal contraceptives. Whether and how another method is affected is not something these labels settle, so that is a question for the prescriber who knows which method you use.
A note on reading this honestly: the Foundayo wording itself says the absorption effect has not been studied in a clinical trial. The advice is precautionary. It is still the advice on the label, and it is the one your prescriber will be working from.
What the pregnancy sections say
Planning a pregnancy
The Wegovy label, section 8.3, says to discontinue the medicine at least 2 months before a planned pregnancy, and explains this is to account for the long half-life of semaglutide. That is a lead time, which means the decision to stop has to come well before conception is attempted, not at the point of a positive test. The label’s reasoning is pharmacological: the drug stays in the body for a while after the last dose.
The Zepbound and Foundayo labels in the sections we reviewed do not state an equivalent number of months. If you are planning to conceive, ask your prescriber how long before to stop the specific medicine you take, rather than assuming the semaglutide figure applies to every product.
When a pregnancy is recognised
All three labels point the same direction. The Zepbound label says weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises patients to discontinue the medicine when a pregnancy is recognised. The Wegovy label says to discontinue it in pregnant patients using it for weight reduction. The Foundayo label says that when a pregnancy is recognised, the patient should be advised of the risk to a fetus and the medicine discontinued.
If you think you may be pregnant, contact your prescriber. The labels leave the next steps to the clinician.
Why this matters more than it might seem
The labels describe two separate issues, and it helps to keep them apart:
- Contraceptive reliability during dose changes, which is a labelled precaution for Zepbound and Foundayo.
- Stopping the medicine ahead of and during pregnancy, which is a labelled instruction on timing and recognition.
People often merge the two. The first is about preventing an unplanned pregnancy while the dose is changing; the second is about what happens once pregnancy is planned or has occurred.
A short list to take to the appointment
| # | Question | Why it matters |
|---|---|---|
| 1 | Which contraceptive method am I using, and does this medicine affect it? | The label wording is about oral hormonal contraceptives specifically. |
| 2 | If I should add or switch methods, for how long, and when does the clock restart? | The label ties the period to initiation and every dose increase. |
| 3 | What is the plan if I vomit or have severe diarrhoea while on an oral pill? | GI side effects are common with these medicines and can interact with how an oral medication is absorbed. Ask for a clear instruction. |
| 4 | If I want to conceive in the next year, when should I stop this medicine? | The Wegovy label gives a minimum lead time; other products may differ. |
| 5 | What should I do first if a pregnancy test is positive? | The labels say to discontinue; the clinician decides what follows. |
Cases where the answer differs
You are switching between products
Because the labels measure the contraceptive precaution from initiation and from each dose escalation, a switch between products may count as a new start. That is an inference from how the labels are written, not a statement in them, so ask directly. Our guide to questions to ask before switching from an injectable to an oral GLP-1 includes the timing questions to raise.
You are taking the Wegovy pill or Foundayo
Both oral products have strict conditions for how and when to take them, and those conditions apply to the tablet itself rather than to your contraceptive. Our explainer on how to take the Wegovy pill covers the timing rules, and Foundayo versus the Wegovy pill compares the two.
You are on a compounded product
Compounded products do not have a manufacturer’s approved label of their own, so none of the instructions above are guaranteed to be reflected in the paperwork you receive. Our articles on whether compounded semaglutide is still legal and on how it differs from Wegovy explain the regulatory gap. If you are on a compounded product, ask the prescriber to tell you in writing what contraceptive and pregnancy advice they are applying.
Who else should read the contraindications
Pregnancy is one of several situations where the labels advise caution. Our guide on who should not take an oral GLP-1 sets out the contraindications and warnings in plain language, and the side effects reported in labels and trials covers the gastrointestinal effects that can matter when you take any oral medication alongside these drugs.
Common misreadings
- “The label says the pill stops working.” It does not. The Zepbound label says efficacy may be reduced, and the Foundayo label says the effect has not been evaluated in a clinical trial. The advice is a precaution.
- “It only matters on the first day.” The labels extend the precaution to each dose escalation.
- “All GLP-1s have the same rule.” The labels we reviewed differ in wording and in the length of the precaution.
- “Two months is for all of them.” The 2-month figure is in the Wegovy label and is tied to semaglutide’s half-life.
Questions people ask
Does this apply to men?
The labels’ pregnancy statements address pregnant patients and people who could become pregnant. The sections we reviewed did not contain an equivalent instruction for partners.
Is there a test that shows whether my pill is still working?
We did not find one described on the labels. Ask your prescriber what they recommend.
Can I rely on a barrier method alone?
The labels give barrier methods as an option alongside switching to a non-oral method. Which combination is right for you is a clinical decision.
Sources
- U.S. FDA labeling, Zepbound (tirzepatide) prescribing information, sections 7, 8.1 and 8.3, checked 5 October 2026.
- U.S. FDA labeling, Foundayo (orforglipron) prescribing information, sections 7, 8.1 and 8.3, checked 5 October 2026.
- U.S. FDA labeling, Wegovy (semaglutide) prescribing information, sections 7, 8.1 and 8.3, checked 5 October 2026.
Medical disclaimer. This article is informational and is not medical advice. It summarises what FDA labels say and does not tell you what to do about contraception or pregnancy planning. Talk to your prescriber before changing, stopping or starting any medicine or contraceptive method.
Keep exploring our GLP-1 resources:
